Tissue-factor targeted peptide amphiphile nanofibers as an injectable therapy to control hemorrhage

Courtney E. Morgan, Amanda W. Dombrowski, Charles M Rubert Pérez, Edward S M Bahnson, Nick D. Tsihlis, Wulin Jiang, Qun Jiang, Janet M. Vercammen, Vivek S. Prakash, Timothy A. Pritts, Samuel I Stupp, Melina R. Kibbe

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Noncompressible torso hemorrhage is a leading cause of mortality in civilian and battlefield trauma. We sought to develop an i.v.-injectable, tissue factor (TF)-targeted nanotherapy to stop hemorrhage. Tissue factor was chosen as a target because it is only exposed to the intravascular space upon vessel disruption. Peptide amphiphile (PA) monomers that self-assemble into nanofibers were chosen as the delivery vehicle. Three TF-binding sequences were identified (EGR, RLM, and RTL), covalently incorporated into the PA backbone, and shown to self-assemble into nanofibers by cryotransmission electron microscopy. Both the RLM and RTL peptides bound recombinant TF in vitro. All three TF-targeted nanofibers bound to the site of punch biopsy-induced liver hemorrhage in vivo, but only RTL nanofibers reduced blood loss versus sham (53% reduction, p < 0.05). Increasing the targeting ligand density of RTL nanofibers yielded qualitatively better binding to the site of injury and greater reductions in blood loss in vivo (p < 0.05). In fact, 100% RTL nanofiber reduced overall blood loss by 60% versus sham (p < 0.05). Evaluation of the biocompatibility of the RTL nanofiber revealed that it did not induce RBC hemolysis, did not induce neutrophil or macrophage inflammation at the site of liver injury, and 70% remained intact in plasma after 30 min. In summary, these studies demonstrate successful binding of peptides to TF in vitro and successful homing of a TF-targeted PA nanofiber to the site of hemorrhage with an associated decrease in blood loss in vivo. Thus, this therapeutic may potentially treat noncompressible hemorrhage.

Original languageEnglish
Pages (from-to)899-909
Number of pages11
JournalACS Nano
Volume10
Issue number1
DOIs
Publication statusPublished - Jan 26 2016

Fingerprint

hemorrhages
Amphiphiles
Thromboplastin
Nanofibers
Peptides
peptides
therapy
Tissue
blood
Blood
liver
Liver
homing
hemolysis
neutrophils
torso
macrophages
punches
mortality
biocompatibility

Keywords

  • Animal model
  • Hemorrhage
  • Hemostasis
  • Nanotherapy
  • Peptide amphiphile
  • Self-assembly
  • Tissue factor

ASJC Scopus subject areas

  • Materials Science(all)
  • Engineering(all)
  • Physics and Astronomy(all)

Cite this

Morgan, C. E., Dombrowski, A. W., Pérez, C. M. R., Bahnson, E. S. M., Tsihlis, N. D., Jiang, W., ... Kibbe, M. R. (2016). Tissue-factor targeted peptide amphiphile nanofibers as an injectable therapy to control hemorrhage. ACS Nano, 10(1), 899-909. https://doi.org/10.1021/acsnano.5b06025

Tissue-factor targeted peptide amphiphile nanofibers as an injectable therapy to control hemorrhage. / Morgan, Courtney E.; Dombrowski, Amanda W.; Pérez, Charles M Rubert; Bahnson, Edward S M; Tsihlis, Nick D.; Jiang, Wulin; Jiang, Qun; Vercammen, Janet M.; Prakash, Vivek S.; Pritts, Timothy A.; Stupp, Samuel I; Kibbe, Melina R.

In: ACS Nano, Vol. 10, No. 1, 26.01.2016, p. 899-909.

Research output: Contribution to journalArticle

Morgan, CE, Dombrowski, AW, Pérez, CMR, Bahnson, ESM, Tsihlis, ND, Jiang, W, Jiang, Q, Vercammen, JM, Prakash, VS, Pritts, TA, Stupp, SI & Kibbe, MR 2016, 'Tissue-factor targeted peptide amphiphile nanofibers as an injectable therapy to control hemorrhage', ACS Nano, vol. 10, no. 1, pp. 899-909. https://doi.org/10.1021/acsnano.5b06025
Morgan CE, Dombrowski AW, Pérez CMR, Bahnson ESM, Tsihlis ND, Jiang W et al. Tissue-factor targeted peptide amphiphile nanofibers as an injectable therapy to control hemorrhage. ACS Nano. 2016 Jan 26;10(1):899-909. https://doi.org/10.1021/acsnano.5b06025
Morgan, Courtney E. ; Dombrowski, Amanda W. ; Pérez, Charles M Rubert ; Bahnson, Edward S M ; Tsihlis, Nick D. ; Jiang, Wulin ; Jiang, Qun ; Vercammen, Janet M. ; Prakash, Vivek S. ; Pritts, Timothy A. ; Stupp, Samuel I ; Kibbe, Melina R. / Tissue-factor targeted peptide amphiphile nanofibers as an injectable therapy to control hemorrhage. In: ACS Nano. 2016 ; Vol. 10, No. 1. pp. 899-909.
@article{e44669828a5e4c64aae86a344dd37dad,
title = "Tissue-factor targeted peptide amphiphile nanofibers as an injectable therapy to control hemorrhage",
abstract = "Noncompressible torso hemorrhage is a leading cause of mortality in civilian and battlefield trauma. We sought to develop an i.v.-injectable, tissue factor (TF)-targeted nanotherapy to stop hemorrhage. Tissue factor was chosen as a target because it is only exposed to the intravascular space upon vessel disruption. Peptide amphiphile (PA) monomers that self-assemble into nanofibers were chosen as the delivery vehicle. Three TF-binding sequences were identified (EGR, RLM, and RTL), covalently incorporated into the PA backbone, and shown to self-assemble into nanofibers by cryotransmission electron microscopy. Both the RLM and RTL peptides bound recombinant TF in vitro. All three TF-targeted nanofibers bound to the site of punch biopsy-induced liver hemorrhage in vivo, but only RTL nanofibers reduced blood loss versus sham (53{\%} reduction, p < 0.05). Increasing the targeting ligand density of RTL nanofibers yielded qualitatively better binding to the site of injury and greater reductions in blood loss in vivo (p < 0.05). In fact, 100{\%} RTL nanofiber reduced overall blood loss by 60{\%} versus sham (p < 0.05). Evaluation of the biocompatibility of the RTL nanofiber revealed that it did not induce RBC hemolysis, did not induce neutrophil or macrophage inflammation at the site of liver injury, and 70{\%} remained intact in plasma after 30 min. In summary, these studies demonstrate successful binding of peptides to TF in vitro and successful homing of a TF-targeted PA nanofiber to the site of hemorrhage with an associated decrease in blood loss in vivo. Thus, this therapeutic may potentially treat noncompressible hemorrhage.",
keywords = "Animal model, Hemorrhage, Hemostasis, Nanotherapy, Peptide amphiphile, Self-assembly, Tissue factor",
author = "Morgan, {Courtney E.} and Dombrowski, {Amanda W.} and P{\'e}rez, {Charles M Rubert} and Bahnson, {Edward S M} and Tsihlis, {Nick D.} and Wulin Jiang and Qun Jiang and Vercammen, {Janet M.} and Prakash, {Vivek S.} and Pritts, {Timothy A.} and Stupp, {Samuel I} and Kibbe, {Melina R.}",
year = "2016",
month = "1",
day = "26",
doi = "10.1021/acsnano.5b06025",
language = "English",
volume = "10",
pages = "899--909",
journal = "ACS Nano",
issn = "1936-0851",
publisher = "American Chemical Society",
number = "1",

}

TY - JOUR

T1 - Tissue-factor targeted peptide amphiphile nanofibers as an injectable therapy to control hemorrhage

AU - Morgan, Courtney E.

AU - Dombrowski, Amanda W.

AU - Pérez, Charles M Rubert

AU - Bahnson, Edward S M

AU - Tsihlis, Nick D.

AU - Jiang, Wulin

AU - Jiang, Qun

AU - Vercammen, Janet M.

AU - Prakash, Vivek S.

AU - Pritts, Timothy A.

AU - Stupp, Samuel I

AU - Kibbe, Melina R.

PY - 2016/1/26

Y1 - 2016/1/26

N2 - Noncompressible torso hemorrhage is a leading cause of mortality in civilian and battlefield trauma. We sought to develop an i.v.-injectable, tissue factor (TF)-targeted nanotherapy to stop hemorrhage. Tissue factor was chosen as a target because it is only exposed to the intravascular space upon vessel disruption. Peptide amphiphile (PA) monomers that self-assemble into nanofibers were chosen as the delivery vehicle. Three TF-binding sequences were identified (EGR, RLM, and RTL), covalently incorporated into the PA backbone, and shown to self-assemble into nanofibers by cryotransmission electron microscopy. Both the RLM and RTL peptides bound recombinant TF in vitro. All three TF-targeted nanofibers bound to the site of punch biopsy-induced liver hemorrhage in vivo, but only RTL nanofibers reduced blood loss versus sham (53% reduction, p < 0.05). Increasing the targeting ligand density of RTL nanofibers yielded qualitatively better binding to the site of injury and greater reductions in blood loss in vivo (p < 0.05). In fact, 100% RTL nanofiber reduced overall blood loss by 60% versus sham (p < 0.05). Evaluation of the biocompatibility of the RTL nanofiber revealed that it did not induce RBC hemolysis, did not induce neutrophil or macrophage inflammation at the site of liver injury, and 70% remained intact in plasma after 30 min. In summary, these studies demonstrate successful binding of peptides to TF in vitro and successful homing of a TF-targeted PA nanofiber to the site of hemorrhage with an associated decrease in blood loss in vivo. Thus, this therapeutic may potentially treat noncompressible hemorrhage.

AB - Noncompressible torso hemorrhage is a leading cause of mortality in civilian and battlefield trauma. We sought to develop an i.v.-injectable, tissue factor (TF)-targeted nanotherapy to stop hemorrhage. Tissue factor was chosen as a target because it is only exposed to the intravascular space upon vessel disruption. Peptide amphiphile (PA) monomers that self-assemble into nanofibers were chosen as the delivery vehicle. Three TF-binding sequences were identified (EGR, RLM, and RTL), covalently incorporated into the PA backbone, and shown to self-assemble into nanofibers by cryotransmission electron microscopy. Both the RLM and RTL peptides bound recombinant TF in vitro. All three TF-targeted nanofibers bound to the site of punch biopsy-induced liver hemorrhage in vivo, but only RTL nanofibers reduced blood loss versus sham (53% reduction, p < 0.05). Increasing the targeting ligand density of RTL nanofibers yielded qualitatively better binding to the site of injury and greater reductions in blood loss in vivo (p < 0.05). In fact, 100% RTL nanofiber reduced overall blood loss by 60% versus sham (p < 0.05). Evaluation of the biocompatibility of the RTL nanofiber revealed that it did not induce RBC hemolysis, did not induce neutrophil or macrophage inflammation at the site of liver injury, and 70% remained intact in plasma after 30 min. In summary, these studies demonstrate successful binding of peptides to TF in vitro and successful homing of a TF-targeted PA nanofiber to the site of hemorrhage with an associated decrease in blood loss in vivo. Thus, this therapeutic may potentially treat noncompressible hemorrhage.

KW - Animal model

KW - Hemorrhage

KW - Hemostasis

KW - Nanotherapy

KW - Peptide amphiphile

KW - Self-assembly

KW - Tissue factor

UR - http://www.scopus.com/inward/record.url?scp=84990990304&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990990304&partnerID=8YFLogxK

U2 - 10.1021/acsnano.5b06025

DO - 10.1021/acsnano.5b06025

M3 - Article

C2 - 26700464

AN - SCOPUS:84990990304

VL - 10

SP - 899

EP - 909

JO - ACS Nano

JF - ACS Nano

SN - 1936-0851

IS - 1

ER -